Sorrento Therapeutics Inc. 
Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company has constructed antibody libraries containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets.
Mr Jaisim Shah
Chief Business Officer
Stanford Universit, School of Medicine
Daria Mochly-Rosen
Professor, Chemical and Systems Biology and Sr Associate Dean for Research
Sun Pharmaceutical Industries, Inc.
|
Sun Pharmaceutical Industries seeks strategic alliance opportunities in CNS, dermatology, oncology, ophthalmology, and respiratory therapeutic areas. Strengthening market presence while maintaining a strong customer focus is a high priority area for the company and its partners. In addition Sun has consolidated its work related to new molecules, specialty products, and innovative drug delivery systems into a subsidiary listed company, namely Sun Pharmaceuticals Advanced Research Company (SPARC). |
|
|
|
Sun Pharmaceutical Industries is a publicly traded international specialty pharma company, commercializing products in 30 markets, also a manufacturer of active pharmaceutical ingredients. In branded markets Sun’s products are prescribed in chronic therapy areas such as neurology, psychiatry, cardiology, gastroenterology, diabetology and respiratory. |
|
|
|
Sun's drive for growth has remained strong since its inception with just five (5) products in 1983. Since 1983, several milestones have been accomplished allowing Sun to emerge as an important specialty pharma company with technically complex products. In addition, Sun is the top pharmaceutical company by market capitalization in India. |
|
|
|
Within the past 15 years Sun has used a combination of internal development and external acquisitions to drive growth. Important mergers have been completed in EU, India, and U.S. including internationally approved manufacturing plants in Ohio, New Jersey, and Tennessee. |
James Hattersley
Vice President of Business DevelopmentSupernus Pharmaceuticals Inc.
Late stage specialty CNS pharmaceutical company with neurology and psych assets looking for partnerships for in and out license.
Dr Woody Bryan
Vice President of Business Development and Licensing
Targacept, Inc.
Our strategy is to selectively collaborate with leading companies with the resources and capabilities to assist us in developing and commercializing some of our product candidates, particularly in target indications for which our collaborator has significant expertise or that involve large primary care markets. We generally seek co-promotion or co-commercialization rights in alliances.
We have a collaboration with AstraZeneca focused in cognitive disorders that includes AZD-3480 and AZD-1446. We have the option to co-promote certain compounds licensed under our cognitive disorders agreement to selected specialist physicians in the US.
We are currently interested in exploring alliances or collaborations for:
• TC-5619, which is in on-going Phase 2 trials in negative symptoms of schizophrenia and ADHD predominantly inattentive subtype; • TC-6499, which in a Phase 2a study showed encouraging potential to enhance GI motility relevant to treating GI/GU disorders such as diabetic gastroparesis and IBS-C/CIC; and • Targacept’s Parkinson’s disease/levodopa-induced dyskinesia program to exploit NNR Therapeutics for symptomatic treatment and disease modification.
We are receptive to evaluating clinical-stage CNS, GI/GU or Orphan opportunities to complement our pipeline.
Jeffrey Brennan
SVP of Business and Commercial Development & Chief Business Officer
Teikoku Pharma USA
Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is an international specialty pharmaceutical company that develops, and manufactures pharmaceutical products. Teikoku focuses its efforts in three therapeutic areas; Pain Management, CNS and Oncology. Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, distributed by Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe. Our core technology platforms include; passive and active transdermal delivery systems as well as injectables. We are currently actively seeking to in-license/acquire later stage product for the US, Europe and Japan.
Mr Francisco Bejar
Director, Business Development
TherapeuticsMD
TherapeuticsMD (TXMD) is a publicly traded Women’s Health company located in South Florida.
TXMD currently has a national sales force calling on OB-GYNs in the US and a strong pipeline of late stage HRT products. We are currently pursuing in-licensing opportunities within the Women’s Health space and considering out-licensing International partners for our 3 late stage HRT products.
